Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis

•CD34-selected stem cell boost improves outcomes for poor graft function after allogeneic hematopoietic stem cell transplantation.•Complete and overall hematologic response rates were 72% and 80%, respectively.•After a median follow-up of 42 months, the actuarial survival rate was 54%.•Rates of acut...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Transplantation and cellular therapy 2021-10, Vol.27 (10), p.877.e1-877.e8
Hauptverfasser:	Shahzad, Moazzam, Siddiqui, Raheel S., Anwar, Iqra, Chaudhary, Sibgha Gull, Ali, Tayyaba, Naseem, Masooma, Ahmed, Tehniat F., Ahmed, Zahoor, Khurana, Sharad, Ahmed, Nausheen, Balusu, Ramesh, Singh, Anurag K., Hematti, Peiman, Callander, Natalie S., Abhyankar, Sunil H., McGuirk, Joseph P., Mushtaq, Muhammad Umair
Format:	Artikel
Sprache:	eng
Schlagworte:	Allogeneic hematopoietic cell transplantation CD34+-selected stem cell boost Graft failure Poor graft function
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	•CD34-selected stem cell boost improves outcomes for poor graft function after allogeneic hematopoietic stem cell transplantation.•Complete and overall hematologic response rates were 72% and 80%, respectively.•After a median follow-up of 42 months, the actuarial survival rate was 54%.•Rates of acute and chronic graft-versus-host disease (GVHD) were 17% and 18%, respectively.•Low CD3+ T cell count in stem cell products directly correlates with the incidence of GVHD. Poor graft function (PGF) is a life-threatening complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) characterized by multilineage cytopenia in the absence of mixed donor chimerism (
ISSN:	2666-6367 2666-6367
DOI:	10.1016/j.jtct.2021.07.012